Naveris
Delivers innovations in technology with the potential to transform cancer detection, drug development, and clinical trials.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | N/A | $17.5m Valuation: $167m | Early VC |
| Total Funding | 000k | ||
Related Content
Naveris is a molecular diagnostics company that develops and commercializes novel blood and saliva tests for the early detection and clinical management of viral-associated cancers. Its flagship product, NavDx, is a blood test that can detect HPV-associated cancers, such as head and neck cancers, at an early stage.
The company's mission is to transform cancer detection, drug development, and clinical trials through its technological innovations. Naveris operates in the biotechnology and healthcare sectors, with a focus on oncology. Its primary clients are healthcare providers, including oncologists and surgeons, who use its diagnostic tools for patient care.
Naveris's business model is centered on the sale of its diagnostic tests. As a commercial-stage life sciences company, it generates revenue by providing these tests to the healthcare market. The company is also involved in drug development and clinical trials, which could represent additional revenue streams or future growth opportunities.
Keywords: molecular diagnostics, cancer detection, blood tests, saliva tests, viral-associated cancers, NavDx, HPV, oncology, biotechnology, life sciences